Evidence map›Paper›PMID 34903795›Full record

ArticleScientific reports2021

Therapeutic interfering particles exploiting viral replication and assembly mechanisms show promising performance: a modelling study.

Farzad Fatehi, Richard J Bingham, Pierre-Philippe Dechant, Peter G Stockley, Reidun Twarock

Open access · goldAbstract read
In one paragraph

Article in Scientific reports, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 4 papers.

0numbers the graph read from it
0cells of the map it votes in
4citing papers in PubMed
0.8field-weighted citation impact, top 26% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

4 citing papers in PubMed, 7 citations in OpenAlex.

  1. Review
  2. Article
  3. Review
  4. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

5 authors at 2 institutions in 1 country.

Farzad Fatehi *York Cross-disciplinary Centre for Systems Analysis, University of York, York, YO10 5GE, UK.
Richard J Bingham *York Cross-disciplinary Centre for Systems Analysis, University of York, York, YO10 5GE, UK.
Pierre-Philippe Dechant *York Cross-disciplinary Centre for Systems Analysis, University of York, York, YO10 5GE, UK.
Peter G StockleyAstbury Centre for Structural Molecular Biology, University of Leeds, Leeds, LS2 9JT, UK. p.g.stockley@leeds.ac.uk.
Reidun TwarockYork Cross-disciplinary Centre for Systems Analysis, University of York, York, YO10 5GE, UK. rt507@york.ac.uk.
University of York · GBUniversity of Leeds · GB

Funding

Wellcome Trust 110145Wellcome Trust 110145/Z/15/ZWellcome Trust 110146
6 · The paper itself

Abstract

Defective interfering particles arise spontaneously during a viral infection as mutants lacking essential parts of the viral genome. Their ability to replicate in the presence of the wild-type (WT) virus (at the expense of viable viral particles) is mimicked and exploited by therapeutic interfering particles. We propose a strategy for the design of therapeutic interfering RNAs (tiRNAs) against positive-sense single-stranded RNA viruses that assemble via packaging signal-mediated assembly. These tiRNAs contain both an optimised version of the virus assembly manual that is encoded by multiple dispersed RNA packaging signals and a replication signal for viral polymerase, but lack any protein coding information. We use an intracellular model for hepatitis C viral (HCV) infection that captures key aspects of the competition dynamics between tiRNAs and viral genomes for virally produced capsid protein and polymerase. We show that only a small increase in the assembly and replication efficiency of the tiRNAs compared with WT virus is required in order to achieve a treatment efficacy greater than 99%. This demonstrates that the proposed tiRNA design could be a promising treatment option for RNA viral infections.

Indexed as

Models, TheoreticalVirus AssemblyVirus ReplicationAntiviral AgentsHepacivirusHepatitis CHumansRNA, ViralVirionAntiviral AgentsRNA, Viral

Identifiers

PMID34903795
PMCPMC8668974
OpenAlexW3188821308

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.